JAN 2 8 2001

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Dahlen et al.

Title:

USE OF B-TYPE NATRIURETIC

PEPTIDE AS A PROGNOSTIC

INDICATOR IN ACUTE **CORONARY SYNDROMES**

Appl. No.:

09/835,298

Filing Date: 04/13/2001

Examiner:

Lam, Ann Y.

Art Unit:

1641

CERTIFICATE OF MAILING hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below. Nancy V. McElrath (Date of Deposit)

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR §1.56**

Mail Stop Amendment - IDS Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

The documents listed on the attached PTO/SB/08 were cited during the prosecution of corresponding European Application No. 02734211.2 (Our Docket No. 071949-6505). A copy of the European Search Report is attached setting forth the portion of each document considered relevant by the examiner. An English-language counterpart of the foreign-language document has not been provided. The absence of a translation or an English-language counterpart document does not relieve the PTO from its duty to consider any submitted document (37 CFR §1.98 and MPEP§609).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Date 0 (20 (2006

FOLEY & LARDNER LLP Customer Number: 30542 Telephone: (858) 847-6722

Facsimile: (

(858) 792-6773

Respectfully submitted,

Richard Warburg, Reg. No. 32,327 By Barry S. Wilson, Reg. No. 39,431

Attorney for Applicant

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control printer.

	Substitute for form	1449B/	PTO	Complete if Known		
09.75	006			Application Number	09/835,298	
JAN 2 9 2	INFORMATION DIS	SCLO	SURE	Filing Date	04/13/2001	
STEEL STEEL	STAYTEMENT BY A	APPLI(CANT	First Named Inventor	Jeffrey R. Dahlen	
Ch	NET CONTRACTOR			Group Art Unit	1641	
PADEN	use as many sheets	as nec	cessary)	Examiner Name	Lam, Ann Y.	
Sheet	1	of	2 ·	Attorney Docket Number	071949-5301	•

U.S. PATENT DOCUMENTS						
Examiner Initials*	0.1	U.S. Patent (Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Cite No. ¹	Number	Kind Code ² (if known)			
· · · · · · · · · · · · · · · · · ·						
			·			

U.S. PATENT APPLICATION DOCUMENTS							
Examiner Initials*	Cite	U.S. Patent Application Document		Name of Detented or Applicant of	Filing Date of	Pages, Columns, Lines, Where Relevant	
	No.1	Serial Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
					•		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Fo Office ³	reign Patent D Number⁴	Nocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	A1	wo	02/083913		Biosite Diagnostics, Inc.	10-24-2002		

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number publisher, city and/or country where published.							
- 1	A2	CASSIN et al., È realizzabile una strategia operative piu efficace per la gestione in urgenza del paziente con dolore toracico acuto?, Ital Heart J Suppl, Feb. 2000, pp. 186-201, Vol. 1						
·	А3	FUTTERMAN et al., Novel Markers in the Acute Coronary Syndrome: BNP, IL-6, PAPP-A, American Journal of Critical Care, March 2002, pp. 168-172, Vol. 11, No. 2						
	A4	HUNT et al., Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment, Clinical Endocrinology, 1997, pp. 287-296, Vol. 47						

Examiner			Date		
Signature			Considered		
	•			1	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO		Complete if Known		
Substitute for form 1443B/F10	Application Number	09/835,298		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	04/13/2001		
STATEMENT BY APPLICANT	First Named Inventor	Jeffrey R. Dahlen		
1 1 M 9 " E/	Group Art Unit	1641		
(use/as many sneets as necessary)	Examiner Name	Lam, Ann Y.		
of 2	Attorney Docket Number	071949-5301		

ERS), title of the article (when appropriate), title of the n, catalog, etc.) date, page(s), volume-issue number(s), r country where published. of circulating natriuretic peptides in cardiovascular Vol. 95, No. 5 opeptide A, Troponin I, Myoglobin, and Myosin Light in Consecutive Patients Presenting to the Emergency 000, pp. 1107-1113, Vol. 102, No. 10
Vol. 95, No. 5 opeptide A, Troponin I, Myoglobin, and Myosin Light in Consecutive Patients Presenting to the Emergency
in Consecutive Patients Presenting to the Emergency
·

Examiner	Date	
Signature	Considered	
,		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.